Tetraphase Pharmaceuticals to Present Data on Preclinical Activity of TP-2846 in Acute Myeloid Leukemia
February 27 2019 - 4:30PM
Business Wire
– Data to be Presented at the 2019 American
Association for Cancer Research Annual Meeting –
– Three Abstracts Selected for Poster
Presentations –
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a
biopharmaceutical company focused on developing and commercializing
novel tetracyclines to treat life-threatening conditions, today
announced it will present three posters on TP-2846, the Company’s
newly revealed pipeline candidate for acute myeloid leukemia (AML).
The posters will be presented at the 2019 American Association for
Clinical Research (AACR) Annual Meeting, taking place March 29 –
April 3 at the Georgia World Congress Center in Atlanta. The poster
presentations will include in vitro and in vivo data supporting
TP-2846’s potential as a novel tetracycline antileukemia agent.
“Decades of research have shown that tetracyclines hold
potential as anticancer agents, but to date, optimizing a
tetracycline for oncology has proven elusive,” said Guy Macdonald,
President and Chief Executive Officer. “Leveraging our proprietary
and productive discovery platform, we identified TP-2846, a
structurally diverse tetracycline and potential new antileukemia
agent with potent in vitro and in vivo activity. We look forward to
further discussing the potential of TP-2846 at AACR and building on
this encouraging preclinical dataset.”
“TP-2846 represents a new mechanism of action with potential
application for AML patients regardless of mutation status,” said
Jacques Dumas, Ph.D., Chief Scientific Officer. “By using our fully
synthetic technology for building tetracyclines, we have been able
to optimize TP-2846 for AML, warranting its further study in this
patient population.”
The details for the data presentations at AACR are as
follows:
Abstract Number: 3857Title: Discovery and
structure-activity relationship studies of TP-2846: a novel
tetracycline antileukemia agentSession Category:
Experimental and Molecular TherapeuticsSession Title: Novel
Antitumor Agents 2Session Date and Time: Tuesday, April 2,
2019 from 1:00 PM - 5:00 PMLocation: Georgia World Congress
Center, Exhibit Hall B, Poster Section 12
Abstract Number: 3880Title: In vivo activities of
TP-2846: a novel tetracycline antileukemia agentSession
Category: Experimental and Molecular TherapeuticsSession
Title: Novel Antitumor Agents 2Session Date and Time:
Tuesday, April 2, 2019 from 1:00 PM - 5:00 PMLocation:
Georgia World Congress Center, Exhibit Hall B, Poster Section
12
Abstract Number: 4802Title: In vitro
characterization of TP-2846: a novel tetracycline antileukemia
agentSession Category: Experimental and Molecular
TherapeuticsSession Title: Novel Antitumor Agents
3Session Date and Time: Wednesday, April 3, 2019 from 8:00
AM - 12:00 PMLocation: Georgia World Congress Center,
Exhibit Hall B, Poster Section 13
About Tetraphase Pharmaceuticals, Inc.Tetraphase
Pharmaceuticals, Inc., is a biopharmaceutical company using its
proprietary chemistry technology to create novel tetracyclines for
serious and life-threatening conditions, including bacterial
infections caused by many of the multidrug-resistant bacteria
highlighted as urgent public health threats by the World Health
Organization and the Centers for Disease Control and Prevention.
The Company has created more than 3,000 novel tetracycline
compounds using its proprietary technology platform. Tetraphase's
lead product XERAVATM (eravacycline) is approved for the treatment
of complicated intra-abdominal infections by the U.S. Food and Drug
Administration and the European Medicines Agency. The Company’s
pipeline includes TP-271 and TP-6076, which are in Phase 1 clinical
trials and TP-2846 which is in preclinical testing for acute
myeloid leukemia. Please visit www.tphase.com for more company
information.
Any statements in this press release about our future
expectations, plans and prospects, including statements regarding
our strategy, future operations, prospects, plans and objectives,
and other statements containing the words "anticipates,"
"believes," "expects," "plans," "will" and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including
whether our product candidates will succeed in clinical trials and
even if the clinical trials are successful, we may never achieve
regulatory approval of such product candidates and other clinical,
regulatory and commercial risk factors discussed in the "Risk
Factors" section of our quarterly report on Form 10-Q for the
period ended September 30, 2018, filed with the Securities and
Exchange Commission on November 9, 2018. In addition, the
forward-looking statements included in this press release represent
our views as of February 27, 2019. We anticipate that subsequent
events and developments will cause our views to change. However,
while we may elect to update these forward-looking statements at
some point in the future, we specifically disclaim any obligation
to do so.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190227005708/en/
Tetraphase PharmaceuticalsJennifer
Viera617-600-7040jviera@tphase.com
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024